EUVIMEDEUVIMED entdecken
Leitlinie

Adherence to national Lynch syndrome testing guidelines for colorectal cancer in an Aotearoa New Zealand hospital-based population

Nejo Joseph, Matthew McGuinness, Cavaghn H Prosser, Georgina Trifinovich, William Xu, Christopher Harmston

New Zealand Medical Journal · 2024

DOI: 10.26635/6965.6551 ↗

Kurz gefasst

Leitlinie in der Zeitschrift New Zealand Medical Journal, 2024. Verfasst von Nejo Joseph und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The University of Auckland, Auckland, New Zealand. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Hereditary Nonpolyposis, Guideline Adherence, Colorectal Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

aim: Lynch syndrome (LS) is estimated to affect 1–3.9% of patients with colorectal cancer (CRC). Testing for LS is important in determining management and establishing surveillance for “Lynch families”. Previous studies have identified poor rates of testing for LS in CRC patients. This study aimed to describe adherence to guidelines for testing of newly diagnosed CRC for LS. methods: A single institution cohort study of patients over 18 years with colorectal adenocarcinoma from 2018–2022 in Te Tai Tokerau, Aotearoa New Zealand was conducted. Rates of baseline immunohistochemistry (IHC) testing for mismatch repair (MMR) deficiency, further testing for MLH1-deficient cases and rates of germline mutational analysis were audited to determine adherence to national guidelines. The rate of LS in newly diagnosed CRC was estimated. results: Six hundred and sixty patients were eligible for universal testing for LS, of which 84% (n=553) completed initial IHC testing. MMR deficiency was reported in 20% (n=114) cases. Eighty-nine percent (n=101) was attributable to MLH1 deficiency, of which 99% (n=100) were appropriately tested for BRAF-V600E mutation. Sixty-four percent (4/11) patients indicated for hypermethylation testing were appropriately tested. Seventeen patients had an indication for germline mutational analysis, of which only 29% (n=5) were tested. The estimated incidence of LS in newly diagnosed CRC was 0.7–3.8%. conclusion: Compliance with initial IHC testing was good. However, there is a need to improve rates of confirmation genetic testing. The incidence of confirmed LS in this study is 0.7%, however this may be as high as 3.9%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal Neoplasms, Hereditary NonpolyposisGuideline AdherenceColorectal NeoplasmsHumansNew ZealandFemaleMaleMiddle AgedAgedAdultGenetic TestingDNA Mismatch RepairPractice Guidelines as TopicMutL Protein Homolog 1Aged, 80 and overImmunohistochemistry

Substanzen

MutL Protein Homolog 1

Autor:innen und Institutionen

  • Department of Surgery, The University of Auckland, Auckland, New Zealand.
  • Department of General Surgery, Whangārei Hospital, Te Tai Tokerau, Whangārei, New Zealand; Department of Surgery, The University of Auckland, Auckland, New Zealand.

Zitieren

APA

Joseph, N., McGuinness, M., Prosser, C. H., Trifinovich, G., Xu, W., & Harmston, C. (2024). Adherence to national Lynch syndrome testing guidelines for colorectal cancer in an Aotearoa New Zealand hospital-based population. New Zealand Medical Journal. https://doi.org/10.26635/6965.6551

Vancouver

Joseph N, McGuinness M, Prosser CH, Trifinovich G, Xu W, Harmston C. Adherence to national Lynch syndrome testing guidelines for colorectal cancer in an Aotearoa New Zealand hospital-based population. New Zealand Medical Journal. 2024. doi:10.26635/6965.6551

BibTeX
@article{Joseph2024,
  author = {Joseph, Nejo and McGuinness, Matthew and Prosser, Cavaghn H and Trifinovich, Georgina and Xu, William and Harmston, Christopher},
  title = {Adherence to national Lynch syndrome testing guidelines for colorectal cancer in an Aotearoa New Zealand hospital-based population},
  journal = {New Zealand Medical Journal},
  year = {2024},
  doi = {10.26635/6965.6551}
}
Kostenlos starten →